Opinion|Videos|January 10, 2025
Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With the recent NCCN update recommending pirtobrutinib as a second line or later option, and in light of the BRUIN CLL-321 data presented at the 2024 American Society of Hematology annual meeting, what factors should oncologists consider when incorporating newer agents like pirtobrutinib into the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)?
- What is the significance of novel Bruton tyrosine kinase (BTK) degraders such as NX-5948, and how might they fill therapeutic gaps in BTK-resistant or intolerant relapsed/refractory CLL populations?
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
3
Postvaccine Hepatitis Reports More Often Serious in Children vs Adults
4
Will Cancer Care Come Home by 2030? PCOC Panelists Differ on Strategy
5